1. Catalog
  2. Endocrine Hypertension and Cardiovascular Effects
Image For Activity Cover
Endocrine Hypertension and Cardiovascular Effects
Course Description
 
Accreditation and Designation Statements
 
Learning Objectives
 
Target Audience
 
Disclosures and Conflicts of Interest
 
Commercial Support
 
List of Faculty
 
Disclaimer
 
Number of Faculty Members
 
Number of Lectures
 
Engaged Member Price
 
Informed Member Price
 
Non-Member Price
 
Purchase URL
https://my.aace.com/manage-subscriptions
Faculty
Richard J. Auchus, MD, PhD, FACE 
Professor
University of Michigan 

Dr. Auchus is the James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine in the Departments of Pharmacology and Internal Medicine in the Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan. He also serves as Section Head of the Endocrinology Service at the Veterans Administration Ann Arbor Healthcare System. Dr. Auchus and his group are active in research projects ranging from basic chemical principles of steroid biosynthetic enzymes and steroid mass spectrometry to clinical trials and translational investigation in disorders of the pituitary, adrenal, ovaries, and testes that cause hypertension, infertility, and obesity. His clinical interests also focus on pituitary, adrenal, and reproductive diseases that involve disorders of steroid production, and he is particularly interested in the care of adults with genetic disorders of steroid biosynthesis and action. He has authored over 280 journal articles and 30 book chapters, and he has lectured in a wide range of national and international conferences. 
Accreditation Information

Accreditation and Designation Statements:

The American College of Endocrinology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Learning Objectives

Through this education, learners will improve their abilities to:

    • Interpret screening, confirmatory, and localization tests for primary aldosteronism.
    • Gauge the probability that a patient with primary aldosteronism will have an aldosterone-producing adenoma and will benefit from surgery.
    • Identify low-renin mineralocorticoid-receptor antagonist-responsive hypertension.

Target Audience

This educational initiative is intended for all members of the endocrine care team.

Disclosure and Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Faculty​

Richard J. Auchus, MD, PhD, FACE
  • Adrenas- Consulting Fees
  • Corcept Therapeutics Inc.- Consulting Fees, Contracted Research
  • Crinetics Pharmaceuticals- Consulting Fees; Diurnal, LTD- Contracted Research
  • H Lundbeck A/S- Consulting Fees
  • Janssen- Consulting Fees
  • Neurocrine- Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
  • Novartis- Consulting Fees, Contracted Research
  • Phase Bio- Consulting Fees
  • Quest Diagnostics- Consulting Fees
  • Recordati Rare Diseases- Consulting Fees
  • Spruce Biosciences- Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received
  • Strongbridge- Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received 


Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Summary
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Powered By